Video
Dr. Wolf Discusses the GEOMETRY Study in MET+ NSCLC
Author(s):
Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non–small cell lung cancer (NSCLC).
Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non—small cell lung cancer (NSCLC).
The GEOMETRY study is evaluating the MET inhibitor capmatinib (INC280) in patients with MET exon 14 mutated or MET amplified advanced NSCLC. Phase II results were presented at the 2018 ESMO Congress. The primary endpoint of the phase II trial was overall response rate (ORR) by blinded independent central review (BIRC) per RECIST v1.1. The secondary endpoint was duration of response by BIRC.
In patients who had received 1 to 2 prior lines of therapy, capmatinib showed clinically meaningful response rates, as well as a manageable toxicity profile. The response to capmatinib was greater in patients with treatment-naive disease with MET exon 14 mutations. The ORR by BIRC in this population was 72%.
